Medicine recalls
|
| |
| Canada: Recall: Mylan-Cinacalcet: Affected lots exceed the established acceptable intake limit for N-nitroso-cinacalcet |
| |
Health Canada announces that Mylan Pharmaceuticals ULC is recalling the following products from retailers because the affected lots exceed the established acceptable intake limit for N-nitroso-cinacalcet:
- Mylan-Cinacalcet 30mg Tablet (lot number: 3188963)
- Mylan-Cinacalcet 60mg Tablet (lot number: 3199204, 3199206)
- Mylan-Cinacalcet 90mg Tablet (lot number: 3188964)
Mylan-Cinacalcet is indicated for the treatment of secondary hyperparathyroidism (HPT) and controls parathyroid hormone levels, calcium and phosphorous levels, and the serum calcium-phosphorous product (Ca x P) in patients with chronic kidney disease receiving dialysis. It is also indicated for the reduction of hypercalcemia in patients with parathyroid carcinoma or primary HPT for whom parathyroidectomy is not clinically appropriate or is contraindicated.
Please refer to the following website in Health Canada for details:
http://recalls-rappels.canada.ca/en/alert-recall/mylan-cinacalcet-affected-lots-exceed-established-acceptable-intake-limit-n-nitroso
In Hong Kong, the above products are not registered pharmaceutical products.
Ends/Thursday, Jul 17, 2025
Issued at HKT 14:45
|
| |
